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ABSTRACT
Objectives: The association between smoking
reduction and mental health is of particular interest
given that many smokers report that smoking offers
mental health benefits. We aimed to assess the
association between smoking reduction and change in
mental health using two different analytical approaches
to determine if there was any evidence of an
association. There were no prior hypotheses.
Design: A secondary analysis of prospective individual
level patient data from 5 merged placebo-controlled
randomised trials of nicotine replacement therapy for
smoking reduction.
Participants: All participants were adult smokers,
selected because they wanted to reduce but not stop
smoking, and had smoked for at least 3 years.
Participants were excluded if they were pregnant,
breastfeeding, under psychiatric care, deemed to be
unfit by a general practitioner, or part of a cessation
programme. 2066 participants were enrolled in the
trials, 177 participants were biologically validated as
prolonged reducers, and 509 as continuing smokers at
both 6-week and 18-week follow-ups.
Primary outcome: Change in mental health from
baseline to an 18-week follow-up was measured using
the emotional well-being subscale on the Short Form
Health Survey-36.
Results: After adjustment for confounding variables,
the differences for reducers compared with continuing
smokers were: regression modelling −0.6 (95% CI
−4.4 to 3.2) and propensity score matching 1.1
(95% CI −2.0 to 4.1).
Conclusions: Smoking reduction, sustained for at
least 12 weeks, was not associated with change in
mental health, suggesting that reducing smoking was
no better or worse for mental health than continuing
smoking. Clinicians offering smoking reduction as a
route to quit can be confident that, on average,
smoking reduction is not associated with negative
change in mental health.
INTRODUCTION
In the UK and in some other countries,
smoking reduction is promoted as a route to
quit or as a harm reduction approach for
smokers who may not be ready to stop
smoking immediately, or who cannot stop.1
There is limited evidence that reduction
itself improves health,2 but clearer evidence
that people who are supported to reduce are
more likely to achieve cessation.3
A signiﬁcant proportion of smokers in
countries with mature tobacco epidemics
report mental health problems.4 Moreover,
smokers with and without mental health pro-
blems report that smoking offers mental
health beneﬁts.5–10 Therefore, the effect of
smoking reduction on mental health is a par-
ticular concern. There is strong evidence
that stopping smoking is associated with
improved mental health, and this improve-
ment may result from breaking the tobacco
withdrawal cycle.11 However, it is not clear
whether reducing daily cigarette consump-
tion is associated with change in mental
health. Two previous studies have reported
no signiﬁcant association between smoking
reduction and mental health; although, both
were small and therefore may have been
insufﬁciently powered to detect associations,
and only one used a standardised measure of
mental health.12 13
Strengths and limitations of this study
▪ The largest study, to date, examining the associ-
ation between smoking reduction and change in
mental health.
▪ Use of a psychometrically sound mental health
measure, which is sensitive to change in mental
health.
▪ Use of propensity score matching to reduce con-
founding and bias from group membership.
▪ Study presents a low risk of bias according to
the Newcastle-Ottawa Scale for Quality
Assessment of Observational Studies.
▪ Loss to follow-up was high, although the rate
was similar to other studies of smoking
interventions.
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No previous literature has discussed the possible
impact of smoking reduction on mental health and how
this may differ from abrupt cessation; however, based on
what is currently known about tobacco and mental
health, there are three possibilities. As the chemical
components in tobacco have a short half-life, psycho-
logical withdrawal symptoms occur shortly after smoking
a cigarette, and these symptoms become more severe
with longer periods of abstinence.14 15 Thus, the ﬁrst
possibility is that by reducing cigarette consumption
and, in turn, increasing the duration between cigarettes,
the smoker may experience longer periods of and more
intense withdrawal symptoms such as irritability,
depressed mood and anxiety, thus leading to worsened
mental health. Mental health may also worsen for some
smokers on reduction if they derive a mental health
beneﬁt from smoking, according to the self-medication
hypothesis.16 Second, there is evidence that higher levels
of tobacco consumption are associated with poorer
mental health,17 18 and that stopping smoking is asso-
ciated with improved mental health.11 Therefore, it
follows that if there is a dose–response association
between tobacco consumption and mental health, redu-
cing tobacco consumption may be associated with
improvements in mental health. The third hypothesis is
that mental health could remain unchanged. After
maintaining reduced cigarette consumption, the smoker
may adapt to their new tobacco consumption level and
their mental health will remain the same. Another
reason it may not change is that the association between
poor mental health and smoking could be caused by a
common factor19 which would not be expected to
change on smoking reduction.
If smoking reduction worsens mental health, this may
not be the most appropriate route to quit for those with
mental health disorders or who are experiencing stress.
However, if smoking reduction improves mental health
or leads to no change, smokers and clinicians can be
reassured that the intervention is unlikely to cause psy-
chological distress. No previous study has adequately
assessed the association, therefore in this study, we
aimed to do so. A randomised study to assess this
hypothesis would be ideal, however, it would not be prac-
tical. Observational methods are useful in this situation
and different statistical approaches offer different bene-
ﬁts and drawbacks, therefore, we aimed to compare two
common methods to assess the association in question.
We conducted a secondary analysis of individual level
patient data of ﬁve randomised trials of treatment for
smoking reduction. We aimed ﬁrst to estimate the associ-
ation using traditional regression modelling with adjust-
ment for covariates, and second, to compare the results
derived from the regression model with those derived
from propensity score matching (PSM). Effect estimates
from PSM provide evidence that an association is not
due to membership bias or observed confounding, and
therefore offer stronger evidence of a causal associ-
ation.20 21 We compared results from these approaches
to determine if there was evidence of an association
between smoking reduction and change in mental
health.
METHOD
This study followed STROBE reporting guidelines for
observational studies.22 PSM procedures were conducted
and reported following criteria outlined by a review of
PSM methodology.23
Study design
This was a secondary analysis of prospective individual
level patient data from ﬁve merged randomised,
placebo-controlled trials (RCTs) of nicotine replacement
therapy (NRT) for smoking reduction. The trials were
carried out to a consistent protocol, in which partici-
pants were encouraged to reduce their smoking as
much as possible with cessation as the end goal and
were not offered any mood management.
Setting
These data were provided by McNeil pharmaceutical
company (see reports of trials for further details K
Haustein. A double-blind, randomized, placebo-
controlled multicentre trial of a nicotine chewing gum
in smoking reduction. Study ID 980-CHC-9021-0013,
unpublished data, 2001 and refs 24–27). The trials were
conducted in university and medical centres in
Denmark, Switzerland, Australia, the USA and Germany.
Study size
There were 2066 participants enrolled in the trials,
which took place between 1997 and 2003. In total, 1035
participants provided smoking data at both 6-week and
18-week follow-ups (ﬁgure 1). Notably, these attrition
rates were similar to other trials of NRT.28
Participants
All participants were adult smokers (aged ≥18 years),
selected because they wanted to reduce but not stop
smoking, and had smoked for at least 3 years.
Figure 1 Flow chart of N participants reporting smoking data
and included in each analysis (PSM, propensity score
matching).
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Participants were excluded if they were pregnant, breast-
feeding, under psychiatric care, deemed to be unﬁt by a
general practitioner, or part of a cessation programme.
At baseline, investigators gathered data on partici-
pants’ demographic details, age started smoking, cigar-
ettes per day (CPD), nicotine dependence (Fagerström
Test of Nicotine Dependence; FTND),29 intention to
reduce, intention to quit, smoking history (eg, number
of previous attempts reduce, longest period without
smoking), self-rated effects from smoking (‘Relief from
smoking questionnaire’) (K Haustein, unpublished data,
2001), mental health (measured by the emotional well-
being subscale on the Short Form Health Survey-36
(SF-36/RAND-36)30–32) (see online supplementary
material for further details of variables). To preserve
anonymity, some demographic data were unavailable for
this secondary analysis.
Participants were followed up to 8–10 times over 1–
2 years, and on each occasion investigators collected
data on CPD, recorded an expired air carbon monoxide
(CO) reading, and measured quality of life and mental
health using the SF-36.
Exposure
We classiﬁed a participant as having achieved prolonged
50% reduction if they reported at least halving their
daily consumption, and a reduction in exhaled CO of at
least 1 part per million (ppm) from the baseline mea-
surements at both 6-week and 18-week follow-ups.25–27 33
We classiﬁed a participant as smoking continuously (ie,
a non-reducer) if they reported smoking at both times
without achieving a 50% reduction. Anyone not meeting
either deﬁnition was excluded from the analysis (ie, par-
ticipants who quit completely).
Outcome
The primary outcome was change in mental health from
baseline (when all participants were smoking) to
18-week follow-up (after at least 12 weeks of prolonged
reduction or continued smoking).
Scores on the SF-36 mental health subscale range
from 0 to 100. In the US general population, the sub-
scale mean and SD are 70.4 (22.0), and scores of
≤38 indicate a probable mental health problem.30–32
A minimum clinically important difference (MCID) on
this mental health subscale has been deﬁned as a
minimum difference between 2.0 and 6.2 points among
exposure groups.32
Analysis
All analyses were conducted using Stata V.13. If partici-
pants were missing any relevant data they were excluded
from the analyses.
Linear regression—In the ﬁrst analysis, we created a
dummy variable representing reduction (reducers=‘1’,
smokers=‘0’), and used linear regression modelling to
examine the association between smoking reduction and
mental health at ﬁnal follow-up with adjustment for
baseline mental health values. Change scores were not
compared between groups because of regression to the
mean when using within-person repeated measures data.
Using change scores can overestimate the effect, there-
fore, it is recommended to use outcome scores with
adjustment for baseline values.34 We then repeated the
model adjusting for FTND score and treatment alloca-
tion (active/placebo), age, sex and trial. We also tested
for an interaction between treatment allocation and
reduction status, to account for the possible effect of
active NRT on psychological withdrawal symptoms in
reducers.35
Propensity score matching—This involved three steps.
First, a logistic regression model was developed using
covariates which predicted whether or not smokers
reduced smoking. Nicotine dependence (FTND) and
treatment allocation36 were forced into the model, and a
forward stepwise procedure was used to add baseline
mental health, intention to reduce (eg, make a serious
attempt to reduce smoking in 1 month), intention to
quit, sex, age, smoking history, CPD, single item ques-
tions from the self-rated ‘Relief from smoking question-
naire’ (eg, report of calming effects from smoking), all
at the p<0.10 level.37 Second, this model was combined
using the PSMATCH2 command in Stata V.13 to calcu-
late each participant’s propensity score. Reducers were
matched to the continuing smoker in the same trial with
the closest propensity score on a ratio of 1:1 using a
nearest neighbour greedy algorithm with no replace-
ments, and matching was restricted to the common
support region. Third, we conducted a series of model
adequacy checks (see online supplementary material).
Finally, to determine the association between smoking
reduction and mental health we repeated the linear
regression model discussed above using the matched
sample.
We developed three sensitivity analyses using different
PSM models. Our adjusted regression model was rerun
for each PSM sensitivity analysis, and we compared the
regression coefﬁcients between the sensitivity models.
The trials measured key baseline variables consistently;
each trial also measured some variables differently to
others. Therefore, we (1) matched participants within
trials using all relevant variables, (2) matched partici-
pants across trials including variables measured consist-
ently and (3) repeated models with and without
common support restrictions (see online supplementary
material).
RESULTS
Baseline characteristics of participants in whole sample
Trial non-completers (n=1342) did not differ greatly
from those who were included in the analysis (table 1).
In total 179 participants were biologically validated as
prolonged reducers at both 6 and 18 weeks, and 545 as
continuing smokers at both follow-ups. No reducers and
six smokers had missing baseline mental health scores,
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and two reducers and 30 smokers had missing mental
health data at follow-up. The mean baseline mental
health scores of those excluded (M=66.7, SD=19.0) and
those included (M=72.6, SD=16.8) indicated that both
groups were psychologically healthy according to the
SF-36 cut-off.30–32 After exclusion for missing mental
health data, 177 participants were biologically validated
as reducers and 509 as continuing smokers (ﬁgure 1).
Table 1 displays baseline characteristics of unmatched
smokers and reducers. The proportion of participants
who received active treatment was greater among redu-
cers than smokers (p<0.0001).
Linear regression modelling
Association between smoking reduction and change in mental
health—mental health scores showed a small improve-
ment from baseline to 18-week follow-up in both groups.
The mean change (SD) in the reducer group was 0.4
(15.7) compared with 1.0 (15.3) in the continuing
smoker group. After adjustment for baseline mental
health values, the difference between groups was −0.1
(95% CI −2.5 to 2.3, p=0.93), indicating that reducers
showed a small decline in mental health compared with
continuing smokers, however, there was no strong evi-
dence for a difference between groups. After further
adjustment for FTND, treatment status, age, sex, treat-
ment status×reduction status, and trial, the difference
between groups was −0.6 (95% CI −4.4 to 3.2, p=0.75).
There was no evidence for an interaction between active
treatment and reduction status.
Propensity score matching approach
Baseline characteristics of participants in propensity score-
matched sample—the main PSM model included 177 bio-
logically validated reducers; one reducer was excluded
because data from the ‘Relief from smoking question-
naire’ was missing. Of the 176 reducers with complete
data, 4 were lost to common support restrictions. Those
excluded for this reason were psychologically healthy,
with mean (SD) SF-36 scores of 70.0 (28.7). Therefore,
172 reducers were matched to 172 smokers with similar
propensity scores (ﬁgure 1). Before PSM, there were dif-
ferences in the proportion of participants receiving
active treatment between exposure groups (table 1).
After matching, the sample, when measured across
trials, was balanced on baseline characteristics (table 2),
although there was weak evidence that mental health
differed between groups (p=0.07).
Association between smoking reduction and mental health in
the propensity score-matched sample—details of the variables
entered into propensity scores and for model adequacy
checks are shown in the online supplementary material.
After matching, reducers showed a small improvement
in mental health of 0.3 (15.9), and this was similar for
smokers who continued 0.7 (15.8). There was no clear
evidence for a difference between groups. After adjust-
ment for baseline mental health, reducers showed an
improvement in mental health compared with continu-
ing smokers; 0.9 (95% CI −2.2 to 3.9; p=0.55). This asso-
ciation was unchanged after adjustment for age and sex
1.1 (95% CI −2.0 to 4.1, p=0.50).
Comparison of statistical approaches
Table 3 presents a summary of effect estimates for the
two statistical approaches. There was no clear evidence
of an association between smoking reduction and
mental health using either approach. Moreover, there
was no consistent evidence of a difference greater than
the MCIDi between exposure groups. However, in all
cases, the CIs included the MCID, and the direction of
effect indicated that the point estimate differed between
the analyses.
Table 2 Baseline characteristics of propensity
score-matched sample
Variable
Smokers
(n=172)
Reducers
(n=172)
Age, mean (SD) 45.0 (10.7) 46.7 (10.7)
Sex, % male (n) 47 (81) 43 (74)
FTND, M (SD) 5.81 (2.1) 5.9 (2.0)
SF-36 mental health, mean (SD) 70.8 (15.7) 73.9 (16.6)
Treatment status, % received
active (n)
60 (104) 62 (107)
FTND, Fagerström Test of Nicotine Dependence; SF-36, Short
Form Health Survey-36.
Table 1 Baseline characteristics of whole sample
Smokers (n=509) Reducers (n=177) Non-completers (n=1342)*
Age, mean (SD) 45.2 (10.6) 46.6 (10.9) 43.2 (10.9)
Sex, % male (n) 41 (229) 42 (75) 45 (610)
FTND, M (SD) 6.0 (2.0) 5.9 (2.0) 6.2 (2.0)
SF-36 mental health, mean (SD) 72.6 (16.7) 73.7 (16.8) 72.3 (16.5)
Treatment status, % received active (n) 46 (232) 63 (112)† 50 (669)
*A small proportion of non-completers were missing some baseline data; baseline FTND scores were available for 1336 non-completers and
1329 non-completers reported baseline SF-36 mental health scores.
†p<0.0001 (results from t tests or χ2 tests as appropriate).
FTND, Fagerström Test of Nicotine Dependence; SF-36, Short Form Health Survey-36.
iMCID=difference of 2.0 to 6.2 points between exposure groups.
4 Taylor G, et al. BMJ Open 2015;5:e007812. doi:10.1136/bmjopen-2015-007812
Open Access
 o
n
 18 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-007812 on 15 May 2015. Downloaded from 
Risk of bias
Risk of bias was assessed using an adapted version of the
Newcastle-Ottawa Scale for assessment of observational
studies.11 38 The scale assesses risk of bias through ascer-
tainment of exposure and outcome and through loss to
follow-up. This study lost one point for high attrition,
scoring 4/5 which indicates a low risk of bias (see online
supplementary material).
DISCUSSION
Comparison of regression and PSM approaches indicated
there was no statistical evidence of an association
between smoking reduction maintained over 12 weeks
and change in mental health. The point estimates
derived using regression and PSM were close to the null,
and the CIs were reasonably precise, albeit just encom-
passing a clinically important difference in the direction
of either an improvement or worsening in mental health.
Strengths and weaknesses
There were some important strengths to this study. Data
were collected following a strict protocol, with biological
validation of smoking reduction status. Mental health
was assessed using a psychometrically sound tool
designed to measure change in general mental health,
rather than the presence or absence of mental health
disorder. Moreover, participants and raters in the trials
were not aware of the study hypothesis, so there were no
demand characteristics which may have biased the
results. PSM methodology matched participants on
factors previously found to predict ability to reduce daily
tobacco consumption, and after PSM, a good balance of
covariates was achieved and extensive sensitivity analysis
showed no evidence that the results were sensitive to the
methodological decisions we made. The Newcastle-
Ottawa score suggests that the results were also unlikely
to result from multiple sources of bias. A weakness of
this study was loss to follow-up, although this rate was
similar to other studies of NRT.28 It is possible that this
introduced bias,39 however we suggest this is unlikely. To
have biased the study, participants who were lost in the
reducer group would have had to have shown the oppos-
ite change in mental health to participants who were
lost from the continuing smokers group, which seems
improbable.
Interpretation
Results from previous studies have similarly reported a
null association;12 13 however, these studies were impre-
cise because they used a small sample or a non-validated
outcome measure which could also have underestimated
the strength of association. This study overcame these
issues by use of a larger sample and a validated measure
of mental health. As with many observational analyses,
our initial approach using regression was at risk of bias
through confounding and group membership. The pro-
pensity score approach can overcome bias through
group membership and offers more control for con-
founding,20 21 but gave a similar result to the regression
modelling in this case. However, the estimates from PSM
were a little more imprecise by reducing the effective
sample size.
Implications
Many smokers and clinicians are reluctant to address
patients’ smoking behaviour for fear that they may cause
harm to mental health.40 41 This study adds to the evi-
dence from previous studies that reducing daily cigarette
consumption was not associated with change in mental
health.12 13 Therefore, on average, clinicians can be con-
ﬁdent that smoking reduction is unlikely to negatively
inﬂuence patients’ mental health.
CONCLUSION
If smoking reduction was found to be associated with
worsened mental health, this could be due to increasing
the duration of withdrawal symptoms,42–45 thus support-
ing the hypothesis that repeated exposure to tobacco
can worsen mental health through the withdrawal
cycle.43–45 Equally, this could indicate that by reducing
the frequency of any psychological beneﬁt of tobacco
the smoker experiences worse mental health.16 However,
based on these data analysed in two ways, the evidence
here was consistent with previous studies and show no
association between smoking reduction and change in
mental health, thus suggesting that on average smoking
reduction is not any better or worse for mental health
than continuing to smoke. Clinicians offering smoking
reduction as a route to quit can be conﬁdent that on
average smoking reduction is not associated with nega-
tive change in mental health.
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